CXCL9 seems a particularly promising target for additional research because several antagonists for its receptor, CXCR3, have been designed that could potentially function as a treatment that targets both inflammation and fibrosis in IBD [22]. The gene discussed is CXCR3; the disease is inflammatory bowel disease.